Intelligent Bio Solutions (INBS) Projected to Announce Quarterly Earnings on Wednesday

Intelligent Bio Solutions (NASDAQ:INBS) is projected to post its Q1 2027 results before the market opens on Wednesday, November 11th. Analysts expect Intelligent Bio Solutions to announce earnings of ($1.31) per share and revenue of $1.40 million for the quarter. Parties can check the company’s upcoming Q1 2027 earnings report page for the latest details on the call scheduled for Monday, November 9, 2026 at 9:30 AM ET.

Intelligent Bio Solutions Trading Up 6.6%

Shares of NASDAQ INBS opened at $1.77 on Wednesday. Intelligent Bio Solutions has a twelve month low of $1.35 and a twelve month high of $24.90. The company has a market capitalization of $5.88 million, a price-to-earnings ratio of -0.20 and a beta of 4.48. The firm has a 50-day moving average of $1.85 and a two-hundred day moving average of $3.17.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Intelligent Bio Solutions in a report on Thursday, October 15th. One investment analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Intelligent Bio Solutions presently has a consensus rating of “Reduce”.

Intelligent Bio Solutions Company Profile

Intelligent Bio Solutions Inc (NASDAQ: INBS) is a life sciences company focused on developing and commercializing non-invasive diagnostic and screening technologies. Its primary product is the Intelligent Bio Solutions Drug Screening System, a portable platform designed to detect drugs of abuse through sweat collected from a person’s fingerprint.

The system uses a disposable drug screening cartridge and a handheld reader to analyze fingerprint sweat and provide results rapidly. The company markets the technology for applications such as workplace testing, law enforcement, rehabilitation programs, and other settings that require convenient, observed drug screening.

Intelligent Bio Solutions was formerly known as GBS Inc and adopted its current name following its acquisition and integration of Intelligent Fingerprinting, a United Kingdom-based developer of fingerprint-based drug screening technology.